Bajaj Healthcare Limited Reports Q4 FY26 Results

Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates, and Formulations, announced its audited financial results for the quarter and year ended 31st March 2026. The company reported a 12.6% revenue growth and a 35% rise in profit before exceptional items in FY26.

Revenue and Profit Growth

The company’s revenue from operations for Q4 FY26 was Rs. 1,530.6 million, showing a slight decline of 0.9% compared to Rs. 1,544.7 million in Q4 FY25. However, for the full year FY26, revenue grew by 12.6% to Rs. 6,110.3 million from Rs. 5,426.0 million in FY25. Profit After Tax (PAT) from continuing operations before exceptional items registered a healthy growth of 19% YoY, reflecting the strength of operational discipline and cost management.

Product Development Milestones

Bajaj Healthcare Limited made significant progress in product development. The company is progressing through Phase III clinical trials for Cenobamate, a novel anti-epileptic molecule, slated for launch in Q2 FY27. Additionally, the bioequivalence study for Suvorexant Tablets was successfully completed, and an application will be filed with DCGI soon. The company also filed 41 DMFs in Q4, bringing the total to 110, strengthening its global regulatory presence.

Looking Ahead

Commenting on the results, Mr. Anil Jain, Managing Director, said, “The quarter was marked by a challenging operating environment driven by continued price erosion in domestic APIs, early impacts of geopolitical disruptions in West Asia including elevated raw material prices. Despite these challenges, the company remains focused on strengthening its core API business and achieving export-led growth while scaling its formulations business with an emphasis on higher-value products. The company is accelerating efforts in peptides, oncology, and CNS, supported by continued investments in manufacturing, capacity expansion, and R&D-led innovation.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Bajaj Healthcare Limited

Bajaj Healthcare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Bajaj falls 9.9% over three months and has not found a floor yet. Thin margins at 8.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -7.2% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 3.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at -7.2% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Bajaj Healthcare Limited.